FINWIRES · TerminalLIVE
FINWIRES

Arrow Electronics Demand, Backlog Improve but Asia Limits Margins, BofA Says

By

Arrow Electronics (ARW) is seeing improving demand and backlog trends, although Asia mix remains a headwind to margin upside, BofA Securities said in a note Wednesday.

The analysts said the company's fundamentals are improving, with backlog extending into Q2/Q3 and book-to-bill firmly above 1, pointing to a healthier demand environment partly supported by artificial intelligence and better near-term revenue visibility.

However, Asia is likely to stay a lower-margin headwind, while pull-forward activity and higher component costs could pressure end demand in H2 2026 and 2027, alongside market expectations that have already moved materially higher.

"We would become more positive if indicators emerge of more stable end market demand," the analysts added.

The analysts said they are raising revenue estimates for 2026 to $39.4 billion from $34.6 billion, for 2027 to $41.7 billion from $36.2 billion, and for 2028 to $43.2 billion from $39.2 billion. Earnings per share projections were also raised to $20.17 from $13.32, to $21.59 from $15.48, and to $24.31 from $16.83 for 2026, 2027, and 2028, respectively.

BofA upgraded Arrow Electronics to neutral from underperform and raised its price target to $233 from $122.

Price: $210.15, Change: $+8.69, Percent Change: +4.31%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP